Wockhardt USA LLC

India launches first indigenous antibiotic 'Nafithromycin' to combat drug-resistant pneumonia, offering 10x efficacy with a three-day treatment regimen. Developed with support from BIRAC, it targets Community-Acquired Bacterial Pneumonia and awaits CDSCO approval.

Union Minister Dr Jitendra Singh launched India's first indigenous antibiotic, Nafithromycin (Miqnaf), developed by Wockhardt with BIRAC support, targeting drug-resistant pneumonia, 10x more effective than azithromycin, with a 3-day regimen, awaiting CDSCO approval.

India launches first indigenous antibiotic Nafithromycin, developed by Wockhardt with BIRAC support, targeting drug-resistant pneumonia. It is ten times more effective than existing options and offers a three-day treatment regimen, marking a significant step in India's fight against Antimicrobial Resistance (AMR).

Dr. Jitendra Singh announces the soft launch of India's first indigenous antibiotic, Nafithromycin, developed by Wockhardt with support from BIRAC. This new antibiotic, ten times more effective than current options, targets drug-resistant pneumonia with a three-day treatment regimen, addressing a global health crisis of antimicrobial resistance.

Lupin Pharmaceuticals plans to launch generic GLP-1 receptor agonists in 2026, targeting India, South Africa, Latin America, the Philippines, and Eastern Europe. The company aims to capitalize on patent expiries by combining in-house development with licensing partnerships. Competitors like Cipla, Dr. Reddy’s, Wockhardt, and Mankind Pharma are also entering the GLP-1 market, driven by high demand for diabetes and obesity treatments.

Wockhardt's Aspart insulin injection highlights the company's comprehensive capabilities in biosimilars R&D, clinical studies, scale-up, and manufacturing.

Wockhardt shares rose 4.3% after filing for approval of its fast-acting insulin analog, Aspart injection, with India's DCGI. The Aspart insulin will be available in cartridges, vials, and prefilled pens, targeting a market size of over Rs 260 crore in India. Wockhardt is also developing additional insulin analogs and GLP-1 agonists to expand its diabetes portfolio.

Wockhardt shares surged 5% on BSE after CDSCO recommended its antibiotic Miqnaf for CABP treatment. Miqnaf, effective against MDR bugs, offers a monotherapy option and demonstrated best-in-class lung concentrations. Wockhardt's market cap stood at Rs 16,025.24 crore.

Indian drug regulator's Subject Expert Committee recommends Wockhardt's Miqnaf, a novel antibiotic for treating Community-Acquired Bacterial Pneumonia (CABP) in adults, based on comprehensive review of clinical studies. Miqnaf, a once-a-day, 3-day treatment, is effective against multi-drug resistant pathogens, potentially reducing hospitalization needs.

Wockhardt submitted phase-3 data for Nafithromycin 400 mg, a pneumonia treatment, to CDSCO. Approval expected within weeks, with launch in India by early 2024. India faces 18 million pneumonia cases annually, with domestic market potential of ₹400-500 crore in 3-5 years. Nafithromycin, an ultra-short-acting oral treatment with 97% success rate, also targets international markets, including Saudi Arabia.